{
  "id": 8524386,
  "title": "AbbVie's Migraine Franchise Scored a Big Win. Is This Dividend King a No-Brainer Buy Right Now?",
  "url": "https://urgent.news/2026/09/19/abbvies-migraine-franchise-scored-a-big-win-is-this-dividend-king-a-8524386",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-19T19:20:00.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/abbvies-migraine-franchise-scored-big-win-dividend-king-no-brainer-buy-right-now"
  },
  "original_language": "en",
  "account": null,
  "summary": "Key PointsAbbVie's Qulipta could be racing toward another label expansion, given a recent clinical trial win.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 3,
    "also_reported_by": [
      {
        "outlet": "Motley Fool",
        "title": "AbbVie's Migraine Franchise Scored a Big Win. Is This Dividend King a No-Brainer Buy Right Now?",
        "url": "https://urgent.news/2026/09/19/abbvies-migraine-franchise-scored-a-big-win-is-this-dividend-king-a",
        "published": "2026-09-19T19:00:00.000Z"
      },
      {
        "outlet": "Yahoo Finance",
        "title": "AbbVie's Migraine Franchise Scored a Big Win. Is This Dividend King a No-Brainer Buy Right Now?",
        "url": "https://urgent.news/2026/09/19/abbvies-migraine-franchise-scored-a-big-win-is-this-dividend-king-a-8525273",
        "published": "2026-09-19T19:20:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}